Triple live vaccine for swine fever, porcine erysipelas, and porcine Pasteurella multocida 

Adopting fully automated bacterial fermentation bioreactor cultivation technology and advanced cell culture technology, the entire process is antibiotic free. One shot of "three defenses", simple and "efficient".

1. Selected high-quality antigens: high original concentration, optimal immunogenicity! Adopting fully automated bacterial fermentation bioreactor cultivation technology and advanced cell culture technology, the entire process is antibiotic free.

2. High antigen content: Swine fever antigen content ≥ 20000 RFID, porcine erysipelas GC42 strain ≥ 7 × 10 ^? CFU live bacteria, porcine Pasteurella multocida EO630 ≥ 3 × 10 ^ 8 CFU live bacteria.

3. High purity: Using self-developed low serum culture technology, the three antigen components are highly purified, and multiple methods are used to detect exogenous viruses, ensuring no contamination by exogenous viruses.

4. High safety: By using endotoxin elimination technology, the endotoxin content in the vaccine is significantly reduced, and the immune effect is indeed reliable, ensuring safety and worry free.

5. Configure specialized diluent: It can effectively reduce stress or allergic reactions caused by vaccination and improve immune efficacy.

Usage and dosage:Recommended immunization program: 1 dose of commercial pig, first dose of stable Tai Lei, second dose of intramuscular injection of pig triple vaccine; One reserve sow, immunized twice before mating, with an interval of one month; One sow, injected during the empty period (14-28 days postpartum); One serving of boars, with two exemptions per year.

Specification packaging:10 bottles/box

Share

Related products